199 related articles for article (PubMed ID: 28915795)
1. Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway.
Kileng H; Bernfort L; Gutteberg T; Moen OS; Kristiansen MG; Paulssen EJ; Berg LK; Florholmen J; Goll R
BMC Infect Dis; 2017 Sep; 17(1):624. PubMed ID: 28915795
[TBL] [Abstract][Full Text] [Related]
2. Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030.
Meijerink H; White RA; Løvlie A; de Blasio BF; Dalgard O; Amundsen EJ; Melum E; Kløvstad H
BMC Infect Dis; 2017 Aug; 17(1):541. PubMed ID: 28774261
[TBL] [Abstract][Full Text] [Related]
3. The burden of hepatitis C in England.
Sweeting MJ; De Angelis D; Brant LJ; Harris HE; Mann AG; Ramsay ME
J Viral Hepat; 2007 Aug; 14(8):570-6. PubMed ID: 17650291
[TBL] [Abstract][Full Text] [Related]
4. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection.
Sypsa V; Touloumi G; Tassopoulos NC; Ketikoglou I; Vafiadis I; Hatzis G; Tsantoulas D; Akriviadis E; Delladetsima J; Demonakou M; Hatzakis A
J Viral Hepat; 2004 Jul; 11(4):366-74. PubMed ID: 15230860
[TBL] [Abstract][Full Text] [Related]
5. Disease burden of chronic hepatitis C in Brazil.
Ferreira PR; Brandão-Mello CE; Estes C; Gonçales Júnior FL; Coelho HS; Razavi H; Cheinquer H; Wolff FH; Ferraz ML; Pessoa MG; Mendes-Correa MC
Braz J Infect Dis; 2015; 19(4):363-8. PubMed ID: 26051505
[TBL] [Abstract][Full Text] [Related]
6. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.
Law MG; Dore GJ; Bath N; Thompson S; Crofts N; Dolan K; Giles W; Gow P; Kaldor J; Loveday S; Powell E; Spencer J; Wodak A
Int J Epidemiol; 2003 Oct; 32(5):717-24. PubMed ID: 14559738
[TBL] [Abstract][Full Text] [Related]
7. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
[TBL] [Abstract][Full Text] [Related]
8. Projecting future complications of chronic hepatitis C in the United States.
Davis GL; Albright JE; Cook SF; Rosenberg DM
Liver Transpl; 2003 Apr; 9(4):331-8. PubMed ID: 12682882
[TBL] [Abstract][Full Text] [Related]
9. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
Bird SM; Goldberg DJ; Hutchinson SJ
J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
[TBL] [Abstract][Full Text] [Related]
10. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.
Kanwal F; Hoang T; Kramer JR; Asch SM; Goetz MB; Zeringue A; Richardson P; El-Serag HB
Gastroenterology; 2011 Apr; 140(4):1182-1188.e1. PubMed ID: 21184757
[TBL] [Abstract][Full Text] [Related]
11. Estimates on HCV disease burden worldwide - filling the gaps.
Wedemeyer H; Dore GJ; Ward JW
J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
[TBL] [Abstract][Full Text] [Related]
12. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments.
Sypsa V; Touloumi G; Papatheodoridis GV; Tassopoulos NC; Ketikoglou I; Vafiadis I; Hatzis G; Tsantoulas D; Akriviadis E; Koutsounas S; Hatzakis A
J Viral Hepat; 2005 Sep; 12(5):543-50. PubMed ID: 16108772
[TBL] [Abstract][Full Text] [Related]
13. Burden of disease and cost of chronic hepatitis C infection in Canada.
Myers RP; Krajden M; Bilodeau M; Kaita K; Marotta P; Peltekian K; Ramji A; Estes C; Razavi H; Sherman M
Can J Gastroenterol Hepatol; 2014 May; 28(5):243-50. PubMed ID: 24839620
[TBL] [Abstract][Full Text] [Related]
14. Forecasting the disease burden of chronic hepatitis C virus in Poland.
Flisiak R; Halota W; Tomasiewicz K; Kostrzewska K; Razavi HA; Gower EE
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):70-6. PubMed ID: 25426979
[TBL] [Abstract][Full Text] [Related]
15. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
16. Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality.
Lehman EM; Wilson ML
J Viral Hepat; 2009 Sep; 16(9):650-8. PubMed ID: 19413698
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
18. Predicted effects of treatment for HCV infection vary among European countries.
Deuffic-Burban S; Deltenre P; Buti M; Stroffolini T; Parkes J; Mühlberger N; Siebert U; Moreno C; Hatzakis A; Rosenberg W; Zeuzem S; Mathurin P
Gastroenterology; 2012 Oct; 143(4):974-85.e14. PubMed ID: 22863764
[TBL] [Abstract][Full Text] [Related]
19. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
[TBL] [Abstract][Full Text] [Related]
20. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
